Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

Naval Daver, MD
Published: Wednesday, Nov 15, 2017



Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah) is for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Daver says that he believes the success seen in this setting with CAR T-cell therapy will spread to adult and older populations, as well.
 
SELECTED
LANGUAGE


Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah) is for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Daver says that he believes the success seen in this setting with CAR T-cell therapy will spread to adult and older populations, as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x